Third Rock Ventures IV, L.P. - Aug 10, 2021 Form 3 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role: 10%+ Owner
Signature: /s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P.
Stock symbol: TNGX
Transactions as of: Aug 10, 2021
Transactions value $: $0
Form type: 3
Date filed: 8/12/2021, 06:24 PM
Next filing: Aug 26, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	TNGX	Common Stock						19.4M	Aug 10, 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On August 10, 2021, Tango Therapeutics, Inc. (f/k/a BCTG Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which BCTG Merger Sub Corp., a wholly-owned subsidiary of the Issuer merged with and into Tango Therapeutics, Inc. ("Tango"). At the effective time of the Business Combination, each share of Tango outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an exchange ratio of approximately 0.34. As a result, the Reporting Persons received 19,363,975 shares of the Issuer's Common Stock in consideration for the equity securities of Tango held by the Reporting Persons prior to the Business Combination.
F2	These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.

Content

On August 10, 2021, Tango Therapeutics, Inc. (f/k/a BCTG Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which BCTG Merger Sub Corp., a wholly-owned subsidiary of the Issuer merged with and into Tango Therapeutics, Inc. ("Tango"). At the effective time of the Business Combination, each share of Tango outstanding as of immediately prior to the effective time was exchanged for shares of Common Stock of the Issuer based on an exchange ratio of approximately 0.34. As a result, the Reporting Persons received 19,363,975 shares of the Issuer's Common Stock in consideration for the equity securities of Tango held by the Reporting Persons prior to the Business Combination.

These shares are directly held by TRV IV. The general partner of TRV IV is Third Rock Ventures GP IV, L.P. ("TRV GP IV"). The general partner of TRV GP IV is TRV GP IV, LLC ("TRV GP IV LLC"). Each of TRV GP IV and TRV GP IV LLC disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.